Clinical Drug Investigation

, Volume 31, Issue 10, pp 717–726 | Cite as

Cost Effectiveness of Cetuximab Concurrent with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Taiwan

A Decision-Tree Analysis
  • Agnes L. F. Chan
  • Henry W. C. Leung
  • Shiao-Feng Huang
Original Research Article

Abstract

Background: Concomitant chemotherapy with radiotherapy is considered to be the standard of care for patients with head and neck cancer and good performance status. However, published reports on the cost effectiveness of this therapeutic approach are extremely rare.

Objective: The aim of this study was to estimate the cost effectiveness of cetuximab combined with radiotherapy compared with radiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck.

Methods: A decision-tree analysis was used to compare cetuximab combined with radiotherapy and radiotherapy alone in the treatment of patients with locally advanced squamous cell carcinoma of the head and neck from the perspective of the national health payer (the Bureau of National Health Insurance [BNHI]) in Taiwan. The model was based on individual patient data extracted from an international phase III trial. The direct medical costs of care were estimated by clinical expert panels based on the reimbursement price of the BNHI (2007 values). One-way sensitivity analyses were performed while varying the costs and clinical parameters.

Results: The incremental cost per quality-adjusted life-year (QALY) for patients receiving radiotherapy in combination with cetuximab compared with radiotherapy alone was $US36992/QALY in the base-case analysis (2007 values). The sensitivity analysis showed the highest net benefit for radiotherapy alone if the cost of cetuximab increased by 50%.

Conclusion: This study demonstrated that the addition of cetuximab to high-dose radiotherapy regimens is likely to be cost effective in Taiwan because the incremental cost per QALY is below the commonly accepted cost-effectiveness threshold.

References

  1. 1.
    National Institute for Health and Clinical Excellence (NICE). Guideline on cancer services: improving outcomes in the head and neck cancers: the manual. London: NICE, 2007Google Scholar
  2. 2.
    Lefebvre JL. Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol 2005; 16 Suppl. 6: vi7–12CrossRefGoogle Scholar
  3. 3.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56(2): 106–30PubMedCrossRefGoogle Scholar
  4. 4.
    Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59: 225–49PubMedCrossRefGoogle Scholar
  5. 5.
    Taiwan Cancer Registry [online]. Available from URL: http://tcr.cph.ntu.edu.tw/main.php?Page=A5B3#t01 [Accessed 2010 2 Jan]
  6. 6.
    Priebe SL, Aleksejuniene J, Dharamsi S. Oral cancer and cultural factors in Asia. Can J Dent Hygiene 2008; 42(6): 291–5Google Scholar
  7. 7.
    Seiwert TY, Cohen EE. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005; 92: 1341–8PubMedCrossRefGoogle Scholar
  8. 8.
    Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355: 949–55PubMedGoogle Scholar
  9. 9.
    Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 2008; 71(3): 676–81PubMedCrossRefGoogle Scholar
  10. 10.
    Harari PM. Promising new advances in head and neck radiotherapy. Ann Oncol 2005; 16Suppl. 6: vi13–9PubMedCrossRefGoogle Scholar
  11. 11.
    Calais G, Alfonsi M, Barset E, et al. Randomization trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081–6PubMedCrossRefGoogle Scholar
  12. 12.
    Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69–76PubMedCrossRefGoogle Scholar
  13. 13.
    Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1161–71PubMedCrossRefGoogle Scholar
  14. 14.
    Nguyen NP, Sallah S, Karlsson U, et al. Combined chemotherapy and radiation therapy for head and neck malignancies: quality of life issues. Cancer 2002; 94: 1131–41PubMedCrossRefGoogle Scholar
  15. 15.
    Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90(11): 824–32PubMedCrossRefGoogle Scholar
  16. 16.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567–78PubMedCrossRefGoogle Scholar
  17. 17.
    Liang K, Ang KK, Milas L, et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003; 57: 246–54PubMedCrossRefGoogle Scholar
  18. 18.
    Bernier J, Schneider D. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J Cancer 2007; 43: 35–45PubMedCrossRefGoogle Scholar
  19. 19.
    Pryor DI, Porceddu SV, Burmeister BH, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 2009; 90(2): 172–6PubMedCrossRefGoogle Scholar
  20. 20.
    Bölke E, Gerber PA, Lammering G, et al. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008; 184(2): 105–10PubMedCrossRefGoogle Scholar
  21. 21.
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11(1): 21–8PubMedCrossRefGoogle Scholar
  22. 22.
    Meltzer MI. Introduction to health economics for physicians. Lancet 2001; 358: 993–8PubMedCrossRefGoogle Scholar
  23. 23.
    Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 2008; 11(5): 791–9PubMedCrossRefGoogle Scholar
  24. 24.
    Lu T, Zhao C, Chen C, et al. An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): preliminary report [abstract no. 5577]. J Clin Oncol 2010; 28: 15sGoogle Scholar
  25. 25.
    Macario A, Chow JL, Dexter F. A Markov computer simulation model of the economics of neuromuscular blockade in patients with acute respiratory distress syndrome. BMC Med Inform Decis Mak 2006; 6: 15PubMedCrossRefGoogle Scholar
  26. 26.
    Löthgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 2000; 9(7): 623–30PubMedCrossRefGoogle Scholar
  27. 27.
    Fee-charging standards for requestingdata from the Bureau of National Health Insurance, Department of Health, Executive Yuan [online]. Available from URL: http://dohlaw.doh.gov.tw/Chi/EngContent.asp?msgid=263&KeyWord= [Accessed 2011 Apr 8]
  28. 28.
    Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7(5): 518–28PubMedCrossRefGoogle Scholar
  29. 29.
    Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006; 332: 699–703PubMedCrossRefGoogle Scholar
  30. 30.
    Caudell JJ, Sawrie SM, Spencer SA, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys 2008; 71(3): 676–81PubMedCrossRefGoogle Scholar
  31. 31.
    Teoh DC, Rodger S, Say J, et al. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer [letters]. Clin Oncol (R Coll Radiol) 2008; 20(9): 717–20CrossRefGoogle Scholar
  32. 32.
    Evans C, Tavakoli M, Crawford B. Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Manage Sci 2004; 7: 43–9CrossRefGoogle Scholar
  33. 33.
    Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18(2 Suppl.): S68–80PubMedCrossRefGoogle Scholar
  34. 34.
    Hout BA, Al MJ, Gordon GS, et al. Costs, effects, and C/E ratios alongside a clinical trial. Health Econ. 1994; 3(5): 309–19PubMedCrossRefGoogle Scholar
  35. 35.
    Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20(3): 332–42PubMedCrossRefGoogle Scholar
  36. 36.
    WHO Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization, 2001Google Scholar
  37. 37.
    NCCN head and neck cancer guidelines. Clinical practice guidelines in oncology (version 1.2007) [online]. Available from URL: http://www.nccn.org [Accessed 2010 Apr 15]
  38. 38.
    Koukourakis MI, Tsoutsou PG, Karpouzis A, et al. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2010; 77(1): 9–15PubMedCrossRefGoogle Scholar
  39. 39.
    ClinicalTrialsFeeds.org. Cetuximab plus radiotherapy versus cisplatin plus radiotherapy in locally advanced head and neck cancer [online]. Available from URL: http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01216020 [Accessed 2011 Apr 17]
  40. 40.
    Cheung YB, Thumboo J, Gao F, et al. Mapping the English and Chinese versions of the Functional Assessment of Cancer Therapy-General to the EQ-5D utility index. Value Health 2009; 12(2): 371–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • Agnes L. F. Chan
    • 1
  • Henry W. C. Leung
    • 2
  • Shiao-Feng Huang
    • 1
  1. 1.Department of PharmacyChi Mei Medical CenterTainanTaiwan
  2. 2.Department of Radiation Oncology, Wang Fang HospitalTaipei Medical UniversityTaipeiTaiwan

Personalised recommendations